&w=3840&q=100)
Beyond the regular 9-5 job: The rise of part-time bike taxi drivers
Md Kaifee Alam New Delhi
Listen to This Article
Rakesh Kumar, 32, works as a sales executive with a Gurugram-based firm between 10 am and 6 pm. His office job pays a modest salary that once covered rent, EMI, and essentials. However, over the last couple of years, that balance has tipped. So, to make ends meet, Kumar has taken to moonlighting — as a bike taxi driver.
'Before heading to the office, I complete at least five or six rides,' he says. 'In the evening, I ride again for two to three hours.' He uses both Ola and Uber to get rides. 'I earn ₹200-300 every day from
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
28 minutes ago
- Hindustan Times
Lodha Developers expects to conclude one or more land deals this year, ahead of its Delhi-NCR foray: Abhishek Lodha
Mumbai-based listed real estate developer Lodha Developers expects to conclude one or more land deals in Delhi-NCR this fiscal, paving the way for its first project launch in the region in the next financial year, Managing Director and CEO Abhishek Lodha said during the Q1FY26 earnings call on July 28. Lodha Developers' market share is expected to be more than double by the end of the decade in MMR, Pune and Bengaluru, according to the company''s investor presentation for the Q1FY26.(Macrotech Developers) Looking to expand into the Delhi-NCR housing market, Lodha said the company aims to acquire at least one land parcel this year to develop its first residential project in the region. The foray will begin with a pilot phase, involving a limited number of projects and a moderate level of investment. Lodha Developers plans to enter the Delhi-NCR real estate market within the next year and aims to launch its first project in the region in the next financial year, the company said. "We expect to enter Delhi NCR in the next 12 months and hope to launch in fiscal 2027. The Delhi NCR is an important market for us to get into. We obviously, as we have done in Pune and Bengaluru, will only enter in a gradual manner. We will be starting off with a pilot phase with a moderate number of projects and a moderate level of investment with a view to understanding better how the market operates and how we build out the supply chain for operations as well as sales," Lodha said during a recent investors' call. "Our focus in this period is, first and foremost, on building our local operating team. We expect that we will conclude one or more land transactions either on a joint development basis or otherwise in the course of this financial year, and hope to launch in the next financial year. But obviously, at this stage, the details are limited. We will provide a more detailed update once the first land transaction is concluded," Lodha said. Also Read: DLF's Rajiv Singh is the richest real estate developer, followed by Mangalprabhat Lodha and family: Grohe-Hurun India Location strategy for Delhi-NCR Responding to a question on which micro-markets Lodha Developers has zeroed in on for launching its first project in Delhi-NCR, he said that 'I think we are looking across the Delhi NCR to make sure that locations fit with our brand's premium positioning.' "At the same time, have attractive dynamics when it comes to supply-demand and also profitability for us. So, we are looking across the board, and we will be able to provide a little bit more specific detail once the first land transaction is concluded. I think at this stage it's just a directional thing that, yes, we expect to be entering the NCR in the next 12 months," Lodha said during the call. Also Read: Lodha versus Lodha: Real estate tycoons settle trademark dispute through mediation Lodha Developers' market share is expected to be more than double by the end of the decade in MMR, Pune and Bengaluru According to the investor presentation shared with the stock exchanges as part of the Q1FY26 quarterly financial results, Lodha Developers' market share will more than double in the Mumbai Metropolitan Region, Pune, and Bengaluru real estate markets by the end of the decade. The company said in the Mumbai Metropolitan Region, its market share as of FY24 is 10%, which is likely to go up to 20% by the end of the decade, followed by 15% in Pune from its existing 5%, and 12% in Bengaluru from 2% currently, the investor's presentation revealed. Also Read: Buying a property is better than renting one: Abhishek Lodha Q1FY26 results The company's sales bookings increased 10% during the April-June period of this fiscal year to ₹4,450 crore. The company's total income increased to ₹3,624.7 crore in Q1FY26 from ₹2,918.3 crore during the same time last year. Lodha Developers has delivered 110 million sq ft of real estate and is currently developing more than 130 million sq ft under its ongoing and planned portfolio.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Pharma Inc gear up for Day 1 launch of obesity drug in March 2026
As the global demand for next-generation diabetes and weight-loss therapies surge, Indian pharmaceutical companies are stepping up preparations to roll out generic versions of semaglutide—a blockbuster GLP-1 receptor agonist—once patent expires around March 2026. The generic launches will be significant, as the prices for the Indian consumer are expected to come down significantly from the current ₹17,000-26000 (monthly), thereby expanding the patient coverage. Dr. Reddy's Laboratories (DRL), Cipla, Sun Pharma, and Mankind Pharma, and others are ramping up peptide manufacturing, forming device partnerships, and aligning regulatory strategies to capture a share of the global GLP-1 market, estimated to cross $150 billion by decade's end. Hyderabad-based DRL is planning Day 1 launches in India and Brazil, part of a 2026 global rollout across 87 countries. 'The semaglutide launch is very important to us,' said CEO Erez Israeli. The company aims to price its product below Novo Nordisk's current ₹17,000 monthly offering. DRL is also working on 26 GLP-1 therapies, backed by a ₹2,700 crore FY26 capex plan to scale peptide and biosimilar production. Cipla is targeting first-wave launches through a mix of in-house and partner filings. 'We see GLP-1 as one of the biggest therapy opportunities in the last five years,' said Umang Vohra, MD and global CEO at the post earnings call. The company is building parts of its GLP-1 supply chain internally while leveraging partnerships to ensure scalability. Cipla is also crafting an affordable strategy for India's price-sensitive market, betting that post-patent price erosion will be offset by volume growth. Mankind Pharma aims to launch both oral and injectable semaglutide generics and is advancing MKP10241, a novel oral obesity drug in Phase 2 trials in Australia. Sun Pharma, meanwhile, is progressing its investigational GLP-1 molecule Utreglutide, targeted for launch in four to five years. It has secured Phase III approval for semaglutide trials in India, even as it reports negligible impact of GLP-1 drugs on its existing diabetes portfolio. The race for a piece of India's ₹628 crore anti-obesity market, however, comes at a time when the Indian courts and drug regulator body are looking to monitor the unregulated use of weight loss drugs. According to sources, the Central Drug Standards Control Organisation (CDSCO) has initiated work to form a panel after the Delhi High Court in July 2025 asked it to consult experts and relevant stakeholders to look into concerns arising out of approval for drug combinations being sold in the market for weight loss. The directive came in response to a public interest litigation filed by fitness entrepreneur Jitendra Chouksey, who had raised concerns about the marketing approval of drugs such as semaglutide, tirzepatide and liraglutide for weight management, despite limited safety data and the absence of India-specific clinical trials. While disposing of the petition, the court asked the drug regulator to respond to the petitioner within three months. At present, India has two officially available semaglutide brands: Rybelsus (oral) and Wegovy (injectable), both from Danish major Novo Nordisk. Rybelsus is approved for treating Type 2 diabetes, while Wegovy was launched in June 2025 for weight management. US-based Eli Lilly's tirzepatide drug, Mounjaro, is also available in India for obesity management. Analysts say the semaglutide opportunity is also fuelling India's peptide manufacturing ecosystem. 'Formulation is no longer enough—companies need full-stack execution,' said Nirali Shah, Pharma Analyst at Ashika Group, pointing to DRL, Cipla, and Sun Pharma's early moves to secure pen delivery partnerships. Contract development and manufacturing organisations (CDMOs) like Anthem Biosciences and Syngene are positioning themselves to capture a larger share of the growing peptide segment. Device manufacturers, too, are scaling up to meet rising demand for injection pens. India's peptide CDMO market, currently valued at $80 million, is growing at a CAGR of 14 per cent and could become a global supplier base for GLP-1 drugs, said Nilaya Varma, CEO of Primus Partners.
Time of India
an hour ago
- Time of India
Citizenship for sale? Why Canadians are joining the Caribbean passport trend
Canadians are increasingly turning to second citizenships in the Caribbean, not for passport power, but for lifestyle, financial planning, and future security . According to industry experts, demand for Caribbean " citizenship by investment " (CBI) programs is rising among Canadians who already possess one of the world's most powerful passports. Instead of using CBI to increase travel access, they're investing in these programs for peace of mind and long-term flexibility. Explore courses from Top Institutes in Please select course: Select a Course Category Technology Public Policy MBA PGDM healthcare Artificial Intelligence MCA Operations Management Finance Leadership Digital Marketing Cybersecurity Data Science Product Management Project Management Others Data Analytics Management Design Thinking Data Science CXO Degree Healthcare others Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details 'Canadians already have strong passports,' said Eric Major, CEO of UK-based Latitude Consultancy, which specializes in citizenship and residency-by-investment. 'So their motivations are usually one of three things: lifestyle, tax planning, or a Plan B, security if things become unstable at home or abroad.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like New Container Houses Indonesia (Prices May Surprise You) Container House | Search ads Search Now Undo The CBI programs , offered by five eastern Caribbean countries, Antigua and Barbuda, Dominica, Grenada, St. Lucia, and St. Kitts and Nevis, allow foreign nationals to obtain citizenship through either a real estate investment or a donation to a government development fund. How to qualify? Live Events To qualify, applicants undergo a rigorous due diligence process. They must hire a licensed firm, submit background checks, undergo medical exams, verify their income, and complete an identity interview. Once approved, they must fulfill the investment requirement, typically US$270,000 to US$300,000 for real estate, before receiving their citizenship certificate and passport. Canadian law permits dual and even multiple citizenships, and there is no legal limit on how many nationalities a Canadian can acquire. However, as Major points out, maintaining ties such as Canadian bank accounts or spending more than six months a year in the country can still trigger Canadian tax obligations. The programs are a significant economic driver for the Caribbean nations. In some countries, CBI revenue contributes as much as 50 percent of GDP. New regional reforms are also taking shape. As of July 1, a draft framework from the Eastern Caribbean Citizenship by Investment Regulatory Authority (ECCIRA) proposes that successful applicants must spend at least 30 days in the country within five years. If they don't, they could face fines of up to 10 percent of their investment and even risk losing their passport. With increasing global instability, demand for second citizenships, once driven by weaker passport holders, is now being led by North Americans.
